Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $8.3MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Chen Yi-kuei | Chief Operating Officer | Aug 14 '26 | Buy | $15.00 | 20,000 | $300,000 | 121,248 | Aug 17 07:32 PM |
| Lin Peter Kuan-how | Chief Financial Officer | Aug 14 '26 | Buy | $15.00 | 26,667 | $400,005 | 48,979 | Aug 17 07:23 PM |
| Chen Hung-wen | Chief Executive Officer | Aug 14 '26 | Buy | $15.00 | 266,667 | $4,000,005 | 1,029,695 | Aug 17 07:13 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.